Trials / Approved For Marketing

Approved For MarketingNCT02969174

Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

Clinical Professor of Shanghai Tongji Hospital

Status: Approved For Marketing
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine · Academic / Other
Sex: All
Age: 12 Weeks – 38 Weeks
Healthy volunteers: —

Summary

To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women. To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).

Detailed description

Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

Conditions

HDFN

Interventions

Type	Name	Description
OTHER	zimin Lu,Guo Sa	chengzhong Liu

Timeline

First posted: 2016-11-21
Last updated: 2016-11-21

Source: ClinicalTrials.gov record NCT02969174. Inclusion in this directory is not an endorsement.